NasdaqGM:IOVABiotechs
Iovance Biotherapeutics (IOVA) Stock Valuation After Australia’s Conditional Approval Of Amtagvi
Why Australia’s conditional approval of Amtagvi matters for Iovance investors
Australia’s Therapeutic Goods Administration has granted conditional approval for Amtagvi, giving Iovance Biotherapeutics (IOVA) a third marketing authorization for its T cell therapy and reinforcing the product’s expanding international footprint in melanoma treatment.
See our latest analysis for Iovance Biotherapeutics.
The Australian green light for Amtagvi comes as Iovance’s share price shows strong recent...